Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-03 — First-Line Antihypertensive Drug Classes: Mechanisms, Selection, and Contraindications

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-03 — First-Line Antihypertensive Drug Classes: Mechanisms, Selection, and Contraindications
Tier: Tier 3

1. A 66-year-old woman presents for a routine visit. She has hypertension, type 2 diabetes with a urine ACR of 320 mg/g, and stage 3a CKD (eGFR 54 mL/min). Her BP is 158/94 mmHg on amlodipine 10 mg alone. Her potassium is 4.2 mEq/L, creatinine 1.4 mg/dL. She reports no cough, no prior angioedema, and no pregnancy plans. Her cardiologist wants to optimize her regimen. Three weeks after adding lisinopril 5 mg, her creatinine is 1.7 mg/dL (a 21% rise) and potassium is 4.9 mEq/L. She feels well. Which of the following most accurately guides management at this point?

A) Discontinue lisinopril immediately — a creatinine rise of any amount in a patient with pre-existing CKD confirms that ACE inhibitors are causing irreversible renal damage and the drug must be stopped permanently
B) Continue lisinopril unchanged and recheck labs in 3 months — a 21% creatinine rise and potassium of 4.9 mEq/L are both within acceptable ranges; no intervention is needed
C) Increase lisinopril to 10 mg — the creatinine rise confirms the drug is working correctly and higher doses provide greater renoprotection; titrating upward will maximize benefit
D) Continue lisinopril at 5 mg with close monitoring — a creatinine rise of 21% is within the acceptable threshold of 30–35% for RAAS initiation in CKD, reflecting expected efferent arteriolar dilation and reduced intraglomerular pressure; potassium of 4.9 mEq/L is borderline but acceptable; recheck potassium and creatinine in 2 weeks; if both remain stable, consider cautious up-titration; if creatinine rises further above 30–35% baseline or potassium exceeds 5.5 mEq/L, hold the dose and investigate for contributing factors
E) Switch lisinopril to an ARB — ARBs do not cause creatinine rises because they preserve more efferent arteriolar tone than ACE inhibitors, making them safer in pre-existing CKD

ANSWER: D

Rationale:

A 21% creatinine rise is within the acceptable 30–35% threshold for RAAS initiation — it reflects the expected hemodynamic effect of efferent arteriolar dilation reducing intraglomerular pressure; this is the mechanism of renoprotection, not a sign of harm; potassium of 4.9 mEq/L is borderline but within the normal range; the appropriate response is to continue at the current dose with close follow-up in 2 weeks to confirm stability before any up-titration; stopping the drug for a creatinine rise within the acceptable threshold denies her the renoprotective benefit for which it was started.

Option A: Option A is incorrect — a 21% creatinine rise is within acceptable limits and reflects expected hemodynamics; it does not indicate irreversible damage and permanent discontinuation is not warranted.
Option B: Option B is incorrect — while continuing is appropriate, 3-month recheck is too long for a borderline potassium of 4.9 mEq/L and a creatinine that has risen; 2-week recheck is appropriate to ensure stability.
Option C: Option C is incorrect — up-titration with a creatinine of 1.7 mg/dL (already risen 21%) and potassium of 4.9 mEq/L at 3 weeks is premature; stability must be confirmed before increasing the dose.
Option E: Option E is incorrect — ARBs cause equivalent creatinine rises through the same efferent arteriolar dilation mechanism; switching does not provide a safer alternative.

2. A 73-year-old man with a 15-year history of hypertension presents with BP 182/108 mmHg at his annual visit. He is on no medications — he stopped taking hydrochlorothiazide 2 years ago because of leg cramps and never followed up. He has no diabetes, no CKD, no heart failure. His ECG shows LVH by voltage criteria. His 10-year ASCVD risk is 22%. Creatinine is 1.0 mg/dL, potassium 4.1 mEq/L. He asks what medication to start. Which of the following most accurately guides initial therapy?

A) Start monotherapy with the lowest dose of any first-line agent and schedule follow-up in 6 months — BP of 182/108 mmHg with LVH and 22% ASCVD risk warrants a cautious single-drug approach to avoid hypotension
B) Start combination therapy with two first-line agents simultaneously — his BP is 52 mmHg above the target of below 130/80 mmHg; the 2017 ACC/AHA guidelines support initiating two-drug combination therapy when BP is more than 20 mmHg above systolic target or more than 10 mmHg above diastolic target; a preferred regimen would be an ACE inhibitor or ARB plus a thiazide or CCB; LVH and high ASCVD risk reinforce the need for prompt effective BP reduction; follow-up in 4 weeks is appropriate
C) Defer pharmacological treatment and recommend lifestyle modification for 6 months — his BP of 182/108 mmHg may improve with sodium restriction and exercise before medications are needed
D) Restart hydrochlorothiazide at the same dose he previously took — since he has prior thiazide experience, restarting the same agent is the most efficient approach regardless of his current BP level or risk profile
E) Start triple therapy immediately with ACE inhibitor, CCB, and thiazide at maximum doses — any BP above 180/100 mmHg requires maximum-dose three-drug therapy from the outset regardless of prior treatment history

ANSWER: B

Rationale:

Combination therapy is appropriate here — his BP is 182/108 mmHg, which is 52 mmHg above the 130 mmHg systolic target; the 2017 ACC/AHA guidelines recommend initiating two-drug combination therapy when BP is more than 20/10 mmHg above target, as monotherapy is unlikely to achieve goal; his LVH (marker of chronic hypertensive end-organ damage), 22% ASCVD risk, and age reinforce the need for prompt and effective BP reduction; a reasonable starting regimen is an ACE inhibitor or ARB combined with a thiazide diuretic or dihydropyridine CCB; follow-up in 4 weeks to assess response and tolerability.

Option A: Option A is incorrect — monotherapy with 6-month follow-up in a patient 52 mmHg above target with LVH and high ASCVD risk is inadequate; combination therapy with earlier follow-up is appropriate.
Option C: Option C is incorrect — lifestyle modification alone is insufficient for BP of 182/108 mmHg with established end-organ damage (LVH) and high cardiovascular risk; pharmacological therapy must be initiated promptly.
Option D: Option D is incorrect — restarting hydrochlorothiazide monotherapy does not address the magnitude of BP elevation or the current guideline recommendation for combination therapy at this BP level; the prior leg cramps also suggest thiazide-associated hypomagnesemia or hypokalemia warranting a different approach.
Option E: Option E is incorrect — maximum-dose three-drug therapy from the outset is excessive and risks first-dose hypotension, syncope, and falls in a 73-year-old; two-drug therapy with titration is the appropriate starting point.

3. A 50-year-old man with hypertension and no other comorbidities is started on ramipril 5 mg. At 3 weeks he calls reporting a swollen tongue that began this morning. He has no throat tightness, no stridor, and his voice is normal. He took diphenhydramine 1 hour ago with no improvement. His BP by home cuff is 132/78 mmHg. Which of the following most accurately describes the correct management of this call?

A) Reassure him that the swelling will resolve with additional antihistamine doses — angioedema from ACE inhibitors is histamine-mediated and responds to diphenhydramine if given in adequate doses; he should take another dose and call back if it worsens
B) Instruct him to go to the emergency department immediately, stop ramipril, and not take any ACE inhibitor again — tongue angioedema from ACE inhibitors is bradykinin-mediated and does not respond to antihistamines; the absence of throat tightness now does not guarantee airway safety as bradykinin-mediated angioedema can progress unpredictably to laryngeal involvement causing life-threatening obstruction; the drug must be permanently discontinued and all ACE inhibitors are permanently contraindicated
C) Tell him to double his ramipril dose — the tongue swelling is a sign of excessive bradykinin effect at the current dose and reducing the dose paradoxically worsens the angioedema; higher doses desensitize the B2 receptor
D) Switch to an ARB immediately by phone and tell him to start it today — ARBs carry no angioedema risk and the switch can be made without emergency evaluation since his airway is currently clear
E) Advise him to apply ice to his tongue and recheck in 4 hours — localized tongue swelling without systemic symptoms can be managed with cold compresses and close observation at home

ANSWER: B

Rationale:

Tongue angioedema on an ACE inhibitor is a medical emergency requiring immediate emergency department evaluation — this is bradykinin-mediated angioedema, which does not respond to antihistamines or corticosteroids; the current absence of throat tightness or stridor does not guarantee safety because bradykinin-mediated angioedema can progress rapidly and unpredictably to laryngeal involvement causing fatal airway obstruction; waiting for worsening symptoms at home risks missing the window for airway intervention; the patient must go immediately to an emergency department; ramipril must be stopped and all ACE inhibitors are permanently contraindicated; the call requires urgent triage, not reassurance.

Option A: Option A is incorrect — bradykinin-mediated angioedema does not respond to antihistamines; diphenhydramine has already failed to improve the swelling, confirming this; additional antihistamine doses will not help and delay appropriate care.
Option C: Option C is incorrect — dose escalation has no pharmacological basis for treating ACE inhibitor angioedema; this is a harmful and fabricated recommendation.
Option D: Option D is incorrect — while switching to an ARB is appropriate long-term after the event resolves, initiating it by phone without emergency evaluation is inappropriate; the immediate priority is airway safety, not drug substitution; ARBs also carry a small cross-reactivity angioedema risk that requires informed discussion.
Option E: Option E is incorrect — home observation with ice for tongue angioedema on an ACE inhibitor is inappropriate and potentially fatal; airway evaluation in an emergency department cannot be deferred.

4. A 61-year-old woman with hypertension, HFrEF (EF 30%), and type 2 diabetes presents for medication review. She is on carvedilol 25 mg twice daily, lisinopril 40 mg daily, furosemide 40 mg daily, and spironolactone 25 mg daily. Her BP is 118/72 mmHg, HR 58 bpm, and she has no edema. Potassium is 5.3 mEq/L and creatinine is 1.6 mg/dL (baseline 1.4 mg/dL). Her urine ACR is 280 mg/g. She has no symptoms of hypotension. Her physician wants to optimize her regimen. Which of the following most accurately identifies the next pharmacological consideration?

A) Add amlodipine for better BP control — her BP of 118/72 mmHg indicates inadequate control and a fourth antihypertensive is needed
B) Increase spironolactone to 50 mg — higher mineralocorticoid receptor antagonist doses provide superior HFrEF mortality benefit and her potassium of 5.3 mEq/L is acceptable for dose escalation
C) Her current regimen is well-optimized for HFrEF and diabetes with albuminuria — however her potassium of 5.3 mEq/L on lisinopril plus spironolactone warrants close monitoring and dietary potassium counseling; her creatinine rise from 1.4 to 1.6 mg/dL (14%) is within acceptable limits for RAAS inhibition; adding a potassium binder such as patiromer would allow the current RAAS regimen to be maintained safely if potassium trends upward; the regimen does not require additional antihypertensive agents given BP of 118/72 mmHg
D) Discontinue spironolactone — the combination of ACE inhibitor plus MRA in a diabetic patient with CKD is too dangerous and must be stopped regardless of the potassium level
E) Switch lisinopril to an ARB to reduce the hyperkalemia risk — ARBs raise potassium less than ACE inhibitors in patients with CKD because receptor blockade produces less complete aldosterone suppression than enzyme inhibition

ANSWER: C

Rationale:

The current regimen is appropriate for her indications — carvedilol and lisinopril address HFrEF mortality benefit; spironolactone adds MRA mortality benefit in HFrEF (RALES trial); furosemide manages volume; lisinopril provides renoprotection for diabetic nephropathy with albuminuria; her BP of 118/72 mmHg is at target and adding antihypertensives would risk symptomatic hypotension; her potassium of 5.3 mEq/L is elevated but manageable — dietary counseling, reducing dietary potassium intake, and consideration of a potassium binder (patiromer or SZC) would allow safe continuation of the RAAS plus MRA combination that is providing multiple benefits; her creatinine rise of 14% is within acceptable limits.

Option A: Option A is incorrect — BP of 118/72 mmHg is at or below target for HFrEF; adding another antihypertensive risks symptomatic hypotension in a patient with reduced cardiac output.
Option B: Option B is incorrect — potassium of 5.3 mEq/L on lisinopril plus spironolactone is already borderline; increasing spironolactone dose would further raise potassium into a dangerous range without an established additional mortality benefit at higher doses in this context.
Option D: Option D is incorrect — the ACE inhibitor plus MRA combination is guideline-recommended in HFrEF (RALES, EMPHASIS-HF evidence for eplerenone) and in diabetic nephropathy with emerging evidence; it is not uniformly contraindicated at a potassium of 5.3 mEq/L with monitoring in place; discontinuation removes proven mortality benefit.
Option E: Option E is incorrect — ARBs and ACE inhibitors produce equivalent aldosterone suppression through the same downstream mechanism; switching classes does not reduce hyperkalemia risk.

5. A 58-year-old man with hypertension and no other comorbidities is started on chlorthalidone 25 mg. At 6 weeks, his BP is 134/82 mmHg and he has no complaints. His labs show: sodium 139 mEq/L, potassium 3.1 mEq/L, glucose 108 mg/dL, uric acid 8.4 mg/dL (baseline 6.2 mg/dL). He has no history of gout. Which of the following most accurately describes the clinical significance of his laboratory findings and guides management?

A) All laboratory findings are within acceptable ranges for a patient on thiazide diuretics — no action is needed and the patient should continue chlorthalidone at the same dose with annual labs
B) The glucose rise to 108 mg/dL confirms that chlorthalidone has caused type 2 diabetes and insulin therapy should be initiated immediately before further hyperglycemia develops
C) The uric acid rise is the most urgent finding — gout is more dangerous than hypokalemia and chlorthalidone must be discontinued immediately and replaced with a loop diuretic which does not affect uric acid
D) Switch to hydrochlorothiazide — the shorter half-life produces less sustained hypokalemia and the uric acid rise will be smaller at equivalent doses compared to chlorthalidone
E) The potassium of 3.1 mEq/L is the most clinically urgent finding — thiazide-induced hypokalemia at this level increases risk of ventricular arrhythmia, particularly in a patient who may develop cardiac disease; options include oral potassium supplementation (40–60 mEq/day), addition of a potassium-sparing agent such as spironolactone or amiloride, or dose reduction; the uric acid rise from 6.2 to 8.4 mg/dL is significant but he has no gout history — dietary counseling and monitoring are appropriate; the glucose rise to 108 mg/dL is mild and warrants dietary counseling and fasting glucose recheck; all three findings require attention but hypokalemia is the priority

ANSWER: E

Rationale:

Potassium of 3.1 mEq/L is the most clinically urgent concern — hypokalemia at this level (normal 3.5–5.0 mEq/L) increases myocardial excitability and the risk of ventricular arrhythmia, particularly problematic if the patient develops concurrent cardiac disease or takes QT-prolonging medications; management options include oral potassium supplementation (typically 40–60 mEq/day in divided doses), addition of a potassium-sparing agent (spironolactone or amiloride — which also complement the thiazide mechanism), or dose reduction to 12.5 mg; the uric acid rise from 6.2 to 8.4 mg/dL is significant and warrants dietary counseling (reduce purine-rich foods, alcohol) and monitoring; if gout develops, switching to losartan (which has a mild uricosuric effect) should be considered; the glucose rise to 108 mg/dL is mild (pre-diabetes range) and warrants dietary counseling and repeat fasting glucose, but not insulin.

Option A: Option A is incorrect — potassium of 3.1 mEq/L requires intervention; this level is below normal and carries arrhythmia risk; annual labs with no action is inappropriate.
Option C: Option C is incorrect — the uric acid rise, while significant, does not require immediate chlorthalidone discontinuation in a patient with no gout history; hypokalemia is more immediately dangerous; loop diuretics increase uric acid through similar mechanisms and are not preferred for uncomplicated hypertension.
Option D: Option D is incorrect — hydrochlorothiazide causes equivalent hypokalemia and uric acid elevation through the same mechanism at comparable doses; switching does not address the problem.
Option B: Option B is incorrect — a glucose of 108 mg/dL is in the pre-diabetes range (100–125 mg/dL), not diagnostic of type 2 diabetes (≥126 mg/dL on two occasions); insulin therapy is not indicated for this glucose level.

6. A 77-year-old woman with hypertension and osteoporosis is brought by her daughter for evaluation. Her BP today is 168/82 mmHg (isolated systolic hypertension). She reports dizziness when standing. Her standing BP drops to 138/70 mmHg (a 30 mmHg systolic drop) — orthostatic hypotension is confirmed. She is on amlodipine 10 mg and hydrochlorothiazide 25 mg. Her daughter reports she has fallen twice in the past month. Which of the following most accurately guides her antihypertensive management?

A) Add a third antihypertensive immediately — her BP of 168/82 mmHg is above target and the orthostatic hypotension is unrelated to her medications
B) Increase the hydrochlorothiazide dose to 50 mg — higher diuretic doses will lower her systolic BP more effectively and the orthostatic hypotension reflects volume repletion that will self-correct
C) The orthostatic hypotension and falls are the immediate priority — amlodipine and hydrochlorothiazide both contribute to orthostatic hypotension in elderly patients; reducing or eliminating the hydrochlorothiazide (which causes volume depletion worsening orthostasis) should be the first step; her falls represent a near-term risk of serious injury that may outweigh the cardiovascular benefit of aggressive BP lowering in a 77-year-old; the 2017 ACC/AHA guidelines acknowledge that in elderly patients with orthostatic hypotension and fall risk, a higher BP target (below 140 mmHg systolic) may be appropriate; non-pharmacological measures (rising slowly, compression stockings, adequate hydration) should be added; her osteoporosis makes fall prevention critical
D) Refer for tilt-table testing before any medication changes — the diagnosis of orthostatic hypotension requires formal autonomic testing before any antihypertensive adjustment is made
E) Switch to a beta-blocker — the negative chronotropic effect will prevent the reflex tachycardia that drives orthostatic hypotension by maintaining cardiac output during position changes

ANSWER: C

Rationale:

Orthostatic hypotension with falls is the most pressing clinical problem in this 77-year-old with osteoporosis — a 30 mmHg orthostatic drop meets the diagnostic criterion (≥20 mmHg systolic or ≥10 mmHg diastolic); the hydrochlorothiazide contributes through volume depletion which worsens the already-impaired baroreceptor response of aging; reducing or stopping HCTZ should be the first pharmacological step; her two recent falls with osteoporosis create high fracture risk that may dominate the risk-benefit calculation; guidelines for elderly patients acknowledge that in those with orthostatic hypotension and fall risk, a less aggressive BP target (systolic below 140 mmHg) may be more appropriate than the standard below 130 mmHg; non-pharmacological measures complement drug adjustment.

Option A: Option A is incorrect — adding a third antihypertensive in a patient with symptomatic orthostatic hypotension and falls would worsen the immediate risk; the orthostatic hypotension is medication-related, not unrelated.
Option B: Option B is incorrect — increasing the diuretic dose would worsen volume depletion and orthostatic hypotension; this is directly contraindicated in this clinical situation.
Option D: Option D is incorrect — tilt-table testing is not required for the diagnosis of orthostatic hypotension; standing BP measurements confirming a drop of ≥20 mmHg systolic establish the diagnosis; delaying medication adjustment for formal autonomic testing is not appropriate given active falls.
Option E: Option E is incorrect — beta-blockers do not treat orthostatic hypotension and would further reduce the baroreceptor-mediated reflex tachycardia that is a compensatory response to standing; they would worsen orthostatic symptoms in this patient.

7. A 45-year-old man with hypertension on no current medications presents for initial evaluation. His BP is 154/96 mmHg on two readings. He has no diabetes, no CKD, no heart failure, and no prior cardiovascular events. His 10-year ASCVD risk is 8%. He is Black. He asks which medication is best for him. His physician is choosing between lisinopril monotherapy and chlorthalidone monotherapy. Which of the following most accurately guides this decision?

A) Lisinopril monotherapy is preferred regardless of race — ACE inhibitors provide superior cardiovascular protection in all hypertensive patients and racial differences in drug response are not pharmacologically significant
B) Chlorthalidone is preferred as initial monotherapy — ALLHAT demonstrated that Black patients have a lower BP response to ACE inhibitor monotherapy compared to thiazide diuretics and CCBs, related to lower renin activity and higher salt sensitivity in this population; chlorthalidone monotherapy is more likely to achieve BP control; ACE inhibitors are not contraindicated but are less effective as monotherapy in Black patients with uncomplicated hypertension; if two-drug therapy were used, adding lisinopril to chlorthalidone would be appropriate
C) Lisinopril is preferred because his 10-year ASCVD risk of 8% indicates he has diabetic nephropathy requiring RAAS inhibition
D) Both drugs are equally effective in Black patients — the ALLHAT data showing differential response are outdated and have been superseded by more recent guidelines that recommend the same first-line therapy regardless of race
E) Neither drug should be used — Black patients with hypertension require ARBs as the only safe first-line antihypertensive class due to the prohibitive angioedema risk with ACE inhibitors and the thiazide-associated diabetes risk

ANSWER: B

Rationale:

Chlorthalidone is the preferred initial monotherapy for this Black patient with uncomplicated hypertension — the ALLHAT trial demonstrated significantly lower BP reductions with lisinopril compared to chlorthalidone and amlodipine in Black patients, and lisinopril was associated with higher stroke rates in this subgroup; the pharmacological explanation relates to lower plasma renin activity and greater volume and salt sensitivity in many Black patients, making volume-depleting and direct vasodilatory strategies more effective than RAAS inhibition as monotherapy; this guidance does not apply when there is a compelling indication for RAAS inhibition (diabetes with albuminuria, HFrEF, post-MI) — in those cases RAAS inhibitors are still indicated regardless of race; his 8% ASCVD risk and absence of diabetes or CKD mean no such compelling indication exists.

Option A: Option A is incorrect — the ALLHAT data demonstrating differential BP response in Black patients are clinically significant and guideline-incorporated; dismissing racial differences in drug response as pharmacologically insignificant contradicts established evidence.
Option C: Option C is incorrect — an ASCVD risk of 8% does not indicate diabetic nephropathy; he has no diabetes mentioned; the ASCVD risk score is a cardiovascular risk tool, not a nephropathy indicator.
Option D: Option D is incorrect — the ALLHAT data remain the basis for current guideline recommendations for initial drug selection in Black patients; they have not been superseded.
Option E: Option E is incorrect — ARBs are not the only safe antihypertensive in Black patients; thiazides and CCBs are specifically recommended as preferred initial therapy; the angioedema risk with ACE inhibitors is higher in Black patients but does not make all other classes except ARBs unsafe.

8. A 52-year-old woman with hypertension, depression managed with sertraline, and no other comorbidities has BP 158/94 mmHg. Her psychiatrist is concerned about drug interactions. Her cardiologist wants to start amlodipine. The psychiatrist asks whether any antihypertensive would interact with sertraline in a clinically significant way. Which of the following most accurately addresses the drug interaction question while guiding antihypertensive selection?

A) Amlodipine is contraindicated with sertraline — dihydropyridine CCBs inhibit CYP2C19, the primary enzyme metabolizing sertraline, causing sertraline toxicity including serotonin syndrome
B) ACE inhibitors are contraindicated with sertraline — bradykinin accumulation from ACE inhibition potentiates the serotonergic effect of sertraline through B2 receptor-mediated serotonin release in the CNS
C) Beta-blockers are the only safe antihypertensives with sertraline — all other classes cause pharmacokinetic interactions with SSRIs through CYP enzyme competition
D) Amlodipine is an appropriate choice — dihydropyridine CCBs do not have clinically significant pharmacodynamic or pharmacokinetic interactions with sertraline; the concern about antihypertensives and SSRIs primarily relates to certain beta-blockers (notably metoprolol) which are metabolized by CYP2D6 — the same enzyme inhibited by sertraline; sertraline inhibition of CYP2D6 can raise metoprolol plasma levels two to fivefold, causing bradycardia and hypotension; amlodipine is metabolized by CYP3A4 and is not significantly affected by sertraline
E) Chlorthalidone is the only antihypertensive without drug interactions with any SSRI — thiazide diuretics have no cytochrome P450 metabolism and are universally safe with all psychotropic medications

ANSWER: D

Rationale:

Amlodipine is an appropriate and safe choice — the clinically relevant drug interaction to be aware of with sertraline involves beta-blockers, particularly metoprolol; sertraline is a moderate inhibitor of CYP2D6, the enzyme that metabolizes metoprolol (and to a lesser extent other beta-blockers); this inhibition can raise metoprolol plasma levels two to fivefold, causing bradycardia, hypotension, and fatigue; if a beta-blocker is needed in a patient on sertraline, choosing one not primarily metabolized by CYP2D6 (such as atenolol, which is renally cleared) is preferable; amlodipine is metabolized by CYP3A4, which sertraline does not significantly inhibit, so no clinically meaningful interaction exists; ACE inhibitors, ARBs, and thiazides also lack significant interaction with sertraline.

Option A: Option A is incorrect — amlodipine does not inhibit CYP2C19; its metabolism through CYP3A4 is not significantly affected by sertraline; serotonin syndrome from this combination is not an established interaction.
Option B: Option B is incorrect — ACE inhibitors do not potentiate serotonergic effects through bradykinin-mediated CNS serotonin release; this is a fabricated mechanism.
Option C: Option C is incorrect — beta-blockers metabolized by CYP2D6 have the most relevant interaction with sertraline; stating that all other classes are unsafe is incorrect; amlodipine, ACE inhibitors, ARBs, and thiazides are all reasonable choices.
Option E: Option E is incorrect — while thiazides are safe with sertraline, the characterization of them as the only universally safe antihypertensive with any SSRI is an overstatement; multiple classes are safe.

9. A 69-year-old man with hypertension on lisinopril 20 mg and amlodipine 10 mg has BP 144/88 mmHg. He has stable COPD (FEV1 58% predicted, on tiotropium and as-needed albuterol). His cardiologist recently diagnosed new HFrEF (EF 35%) following a hospitalization for dyspnea. The cardiologist wants to add a beta-blocker. His pulmonologist objects citing the COPD. Which of the following most accurately resolves this clinical conflict?

A) The pulmonologist is correct — any beta-blocker is absolutely contraindicated in COPD with FEV1 below 60% and HFrEF must be managed with alternative agents; verapamil should replace the proposed beta-blocker
B) The cardiologist is correct — a cardioselective beta-1 blocker (bisoprolol or metoprolol succinate) should be initiated at low dose and titrated cautiously; the HFrEF mortality benefit of beta-blockers is substantial and well-established; COPD is a relative, not absolute, contraindication; FEV1 of 58% represents moderate COPD and cardioselective agents at low doses are generally tolerated; baseline spirometry should be obtained, the pulmonologist should monitor respiratory status, and the patient should be educated about worsening dyspnea; carvedilol (non-selective) should be avoided
C) Neither drug class is appropriate — the patient should be treated with digoxin alone for HFrEF rate control and contractility support, avoiding both beta-blockers and CCBs
D) Add verapamil as a compromise — non-dihydropyridine CCBs provide rate control similar to beta-blockers in HFrEF without the bronchospasm risk and represent the pharmacologically optimal middle ground
E) The beta-blocker decision should be deferred indefinitely until the COPD has been treated to FEV1 above 70% — HFrEF mortality benefit from beta-blockers only applies to patients with normal lung function

ANSWER: B

Rationale:

The cardiologist is correct — HFrEF is a compelling indication for beta-blockers with substantial proven mortality benefit (MERIT-HF, COPERNICUS, CIBIS-II); moderate COPD (FEV1 58%) is a relative, not absolute, contraindication; cardioselective beta-1 blockers (bisoprolol, metoprolol succinate) have significantly less beta-2 blockade than non-selective agents and are generally tolerated in moderate stable COPD; the approach is low starting dose with careful slow titration, baseline and follow-up spirometry, close coordination with pulmonology, and patient counseling about respiratory symptoms; carvedilol is non-selective and should be avoided; multiple real-world studies have demonstrated that cardioselective beta-blockers can be safely used in COPD with appropriate monitoring.

Option A: Option A is incorrect — COPD is a relative contraindication, not absolute; verapamil is specifically contraindicated in HFrEF with reduced EF due to negative inotropy; it does not provide the mortality benefit of beta-blockers in HFrEF.
Option C: Option C is incorrect — digoxin has a very narrow role in HFrEF (rate control in AF, symptom improvement) and does not provide the mortality benefit demonstrated for beta-blockers; avoiding proven mortality-improving therapy is not justified.
Option D: Option D is incorrect — verapamil is specifically contraindicated in HFrEF with reduced EF due to negative inotropic effects that worsen the cardiomyopathy; characterizing it as a pharmacological compromise is incorrect and dangerous.
Option E: Option E is incorrect — there is no threshold FEV1 above which beta-blockers provide HFrEF mortality benefit that does not apply below it; the evidence applies regardless of lung function, with appropriate agent selection and monitoring in COPD patients.

10. A 55-year-old man with hypertension is being evaluated for a new antihypertensive. His BP is 162/98 mmHg. He has no diabetes, CKD, or heart failure. He recently started celecoxib 200 mg twice daily for osteoarthritis. His previous physician tried lisinopril 10 mg, which controlled his BP well for 2 years, but his BP rose to 158/96 mmHg after starting celecoxib 6 months ago and has not improved despite increasing lisinopril to 20 mg. Which of the following most accurately explains the mechanism of his BP rise and guides management?

A) Celecoxib raises BP through selective COX-2 inhibition — COX-2 derived prostacyclin (PGI2) in vascular endothelium normally counterbalances thromboxane A2-mediated vasoconstriction; selective COX-2 inhibition reduces prostacyclin without reducing thromboxane, shifting the balance toward vasoconstriction and sodium retention; this blunts the antihypertensive effect of lisinopril particularly through volume expansion that reduces the RAAS-dependent component of BP control; the appropriate management is to switch celecoxib to acetaminophen or a non-selective NSAID at the lowest effective dose, or add a diuretic to address the volume-mediated BP rise
B) Celecoxib raises BP through dopamine receptor antagonism in the renal tubule — reduced dopaminergic inhibition of sodium reabsorption increases volume and blunts the ACE inhibitor effect
C) Celecoxib reduces lisinopril absorption from the gastrointestinal tract through COX-2-mediated inhibition of intestinal ACE expression, reducing the drug's bioavailability by 60%
D) The BP rise is caused by celecoxib-induced adrenal aldosterone secretion through COX-2 mediated stimulation of the zona glomerulosa — the resulting mineralocorticoid excess overwhelms the ACE inhibitor's ability to suppress aldosterone
E) Celecoxib is safe in hypertension and has no effect on BP — the rise to 158/96 mmHg reflects natural hypertension progression unrelated to the NSAID; increasing the lisinopril further to 40 mg will restore control

ANSWER: A

Rationale:

Celecoxib is a selective COX-2 inhibitor and raises BP through an established mechanism — COX-2 in vascular endothelium produces prostacyclin (PGI2), a vasodilator and natriuretic prostaglandin; selective COX-2 inhibition reduces PGI2 without reducing thromboxane A2 (which is COX-1 derived), shifting the eicosanoid balance toward vasoconstriction and sodium retention; this volume-mediated BP rise blunts the effect of ACE inhibitors and other antihypertensives; COX-2 inhibitors have a greater effect on BP than traditional NSAIDs in some analyses; management options include switching to acetaminophen (no effect on BP), adding a diuretic (chlorthalidone) to counteract the sodium retention, or accepting a higher BP target if celecoxib cannot be discontinued.

Option B: Option B is incorrect — celecoxib does not antagonize renal tubular dopamine receptors; this is a fabricated mechanism.
Option C: Option C is incorrect — celecoxib does not reduce lisinopril bioavailability through intestinal ACE expression inhibition; this is a fabricated pharmacokinetic interaction.
Option D: Option D is incorrect — celecoxib does not stimulate adrenal aldosterone secretion through zona glomerulosa COX-2; this is a fabricated mechanism; the aldosterone pathway is not the primary driver of celecoxib-induced hypertension.
Option E: Option E is incorrect — the temporal relationship between celecoxib initiation and BP rise (6 months ago, coinciding with drug start) makes drug causation the most likely explanation; COX-2 inhibitor-induced hypertension is well-established; attributing it to natural progression and simply increasing the ACE inhibitor dose does not address the root cause.

11. A 64-year-old woman with hypertension is on chlorthalidone 25 mg, amlodipine 10 mg, and ramipril 10 mg with BP 128/78 mmHg. She is brought to the emergency department after being found confused at home. Her daughter says she has had diarrhea for 4 days and has been unable to keep food or fluids down. Her labs show: sodium 131 mEq/L, potassium 3.0 mEq/L, creatinine 2.8 mg/dL (baseline 1.1 mg/dL), BP 96/58 mmHg. Which of the following most accurately explains her presentation and guides immediate management?

A) She has developed primary aldosteronism as a complication of long-term chlorthalidone use — the hyponatremia and hypokalemia confirm autonomous aldosterone secretion that has overwhelmed her antihypertensive regimen
B) Her presentation represents acute-on-chronic kidney disease from ramipril nephrotoxicity — the creatinine rise confirms that long-term ACE inhibition has caused cumulative irreversible renal damage and ramipril must be permanently discontinued
C) She has volume depletion from gastrointestinal losses causing acute kidney injury, hyponatremia, and hypokalemia — her three-drug antihypertensive regimen (chlorthalidone causing natriuresis and kaliuresis, ramipril reducing efferent arteriolar tone impairing autoregulation of GFR in the volume-depleted state, and amlodipine causing vasodilation) has compounded the hemodynamic consequence of volume depletion; immediate management is IV fluid resuscitation, holding all antihypertensives until volume and BP are restored, electrolyte replacement, and close renal function monitoring; antihypertensives can be carefully reintroduced once she has recovered
D) Her confusion is caused by amlodipine-induced cerebral calcium channel blockade impairing neuronal function — this is a known CNS adverse effect of dihydropyridine CCBs at high doses that resolves with drug discontinuation
E) She needs emergent dialysis — the creatinine of 2.8 mg/dL in a patient on an ACE inhibitor represents end-stage renal disease requiring immediate renal replacement therapy

ANSWER: C

Rationale:

This is volume depletion-driven acute kidney injury compounded by her antihypertensive regimen — 4 days of diarrhea and vomiting has caused significant intravascular volume depletion; chlorthalidone continues to promote natriuresis and kaliuresis even in the volume-depleted state; ramipril reduces efferent arteriolar tone, impairing the renal autoregulatory response that normally maintains GFR during hypoperfusion (bilateral efferent dilation plus volume depletion causes GFR to fall precipitously); amlodipine contributes vasodilation that lowers BP further; the resulting AKI is prerenal, the hyponatremia is dilutional from non-osmotic ADH release during volume depletion, and the hypokalemia reflects ongoing chlorthalidone effect plus GI losses; treatment is IV fluid resuscitation, all antihypertensives held, electrolyte replacement, and serial renal function monitoring; this is the "sick day rules" scenario — patients on diuretics and RAAS inhibitors should hold these drugs during significant GI illness.

Option A: Option A is incorrect — primary aldosteronism causes hypokalemia and hypertension, not hypotension and AKI; the presentation is volume depletion, not hyperaldosteronism; long-term chlorthalidone does not cause primary aldosteronism.
Option B: Option B is incorrect — the creatinine rise is consistent with prerenal AKI from volume depletion, which is hemodynamic and reversible; describing it as cumulative ACE inhibitor nephrotoxicity causing irreversible damage is incorrect; ACE inhibitors do not cause cumulative nephrotoxicity in this way.
Option D: Option D is incorrect — dihydropyridine CCBs do not cross the blood-brain barrier in clinically significant amounts at therapeutic doses; amlodipine does not cause CNS depression or confusion through neuronal calcium channel blockade.
Option E: Option E is incorrect — a creatinine of 2.8 mg/dL does not represent end-stage renal disease; her baseline creatinine of 1.1 mg/dL indicates this is acute and almost certainly reversible with volume resuscitation; emergent dialysis is not indicated.